Immunohistochemistry Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

The Immunohistochemistry Market was valued at USD 2.38 Billion in 2024, and is expected to reach USD 3.56 Billion by 2030, rising at a CAGR of 6.90%. The global Immunohistochemistry market is undergoing substantial growth, fueled by key drivers such as technological innovation, increasing demand for consumer-driven healthcare, the rising incidence of chronic diseases, and a growing focus on preventive care. Immunohistochemistry products ranging from blood tests and pregnancy kits to glucose monitors and allergy testing solutions are progressively becoming integral tools for individuals managing their own health. These devices enable users to monitor a variety of health parameters independently, eliminating the need for clinical visits and empowering consumers to take control of their health.

The market's growth trajectory remains robust, underpinned by advancements in diagnostic technologies, heightened consumer health consciousness, and a shift toward more affordable, accessible, and personalized health solutions. As these Immunohistochemistry products become increasingly central to health management strategies, the market is expected to continue expanding. Regulatory support and ongoing innovations in diagnostics further enhance the market's potential, positioning the Immunohistochemistry segment as a lucrative opportunity for stakeholders in the healthcare and diagnostics industries.

Key Market Drivers

Rising Incidence of Chronic and Infectious Diseases

The global surge in chronic and infectious diseases has become one of the most significant demand drivers for the Immunohistochemistry (IHC) market. This trend is not only reshaping diagnostic approaches but also creating sustained growth opportunities for IHC-related products and services across healthcare systems worldwide. Chronic diseases represent the primary driver of global mortality and long-term disability, exerting substantial pressure on healthcare systems and economies. In 2020, these conditions such as cancer, cardiovascular disease, and diabetes were responsible for or contributed to 79% of all deaths worldwide.

This figure is expected to rise to 84% by 2030, underscoring the urgent need for advanced diagnostic and therapeutic solutions, particularly in high-burden regions and aging populations. As the prevalence of chronic diseases particularly cancer, cardiovascular disorders, diabetes, and autoimmune conditions continues to rise globally, the need for precise, tissue-based diagnostic techniques has become critical.

Immunohistochemistry, which allows for the detection of specific antigens in cells of a tissue section using labeled antibodies, is widely regarded as a gold-standard diagnostic tool, particularly in oncology. The technique aids in tumor classification, grading, and staging, directly influencing treatment decisions. In oncology, IHC is essential in detecting biomarkers such as HER2, Ki-67, and PD-L1, which guide targeted therapy. In autoimmune diseases, IHC helps identify inflammatory markers and immune cell infiltration patterns.

Malaria continues to pose a critical public health challenge, with approximately 249 million cases and over 608,000 deaths reported annually, disproportionately affecting children under the age of five in sub-Saharan Africa. Dengue presents an equally pressing concern, placing over 3.9 billion people globally at risk. The disease leads to millions of infections and thousands of fatalities each year, particularly in densely populated urban regions across Asia and Latin America. With the re-emergence and evolution of infectious diseases (e.g., tuberculosis, HIV, hepatitis, and most recently, COVID-19), there is growing interest in applying IHC techniques to pathogen detection and tissue-based immune response analysis.

IHC is particularly useful in understanding the histopathological impact of viruses and bacteria on human tissues, which plays a crucial role in research and case-specific diagnosis, especially in post-mortem and advanced-stage analyses. This has been further amplified by the COVID-19 pandemic, which increased awareness of tissue-based diagnostic tools to study viral impact at the cellular level, thereby expanding the IHC use case beyond traditional cancer diagnostics. The World Health Organization (WHO) projects that non-communicable diseases (NCDs) will account for nearly 75% of all deaths by 2030. This projection is influencing both public and private healthcare institutions to adopt early and accurate diagnostic frameworks, where IHC plays a vital role. Simultaneously, growing healthcare spending especially in emerging economies is increasing access to sophisticated diagnostic platforms.

Key Market Challenges

High Cost of Instruments and Reagents

Despite the growing demand for immunohistochemistry in clinical diagnostics and pharmaceutical research, the high capital and operational costs associated with IHC instruments and reagents remain a significant barrier to market expansion, particularly in low- and middle-income countries (LMICs). Advanced IHC systems - including automated slide stainers, image analyzers, and digital pathology platforms require substantial upfront investment.

Recurrent costs of high-quality primary and secondary antibodies, detection kits, and substrate reagents are also high, especially for multiplexed or customized panels. Smaller pathology labs and diagnostic centers in emerging markets often lack the budget or funding mechanisms to acquire and maintain these systems, limiting the adoption of IHC technology. This cost barrier not only restricts market penetration in cost-sensitive regions but also slows down lab modernization in under-resourced healthcare systems.

Key Market Trends

Integration of Digital Pathology and Artificial Intelligence (AI) with IHC

The convergence of immunohistochemistry with digital pathology and AI-driven image analysis is redefining how tissue diagnostics are performed and interpreted. This trend is not only enhancing diagnostic accuracy but also improving scalability, standardization, and workflow efficiency. Digital slide scanners now allow high-resolution imaging of IHC-stained tissue, enabling remote diagnosis, archiving, and secondary consultations. AI algorithms are being developed to automatically quantify biomarker expression, such as HER2 or PD-L1, minimizing subjectivity and variability in interpretation.

AI-assisted platforms are accelerating the turnaround time for high-volume labs and facilitating telepathology, especially in resource-constrained or rural areas. This trend is transforming IHC from a manual, pathologist-driven technique to a more automated, data-driven process, making it attractive to both clinical and research sectors and opening up opportunities for scalable global adoption.

Key Market Players

• Thermo Fisher Scientific Inc
• F. Hoffmann-La Roche Ltd.
• Merck KGaA
• Danaher Corporation
• PerkinElmer U.S. LLC
• Bio-Rad Laboratories, Inc.
• Cell Signaling Technology, Inc.
• Bio SB
• Agilent Technologies, Inc.
• Abcam Limited

Report Scope:

In this report, the Global Immunohistochemistry Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Immunohistochemistry Market, By Product:

• Antibodies
• Equipment
• Reagents
• Kits

Immunohistochemistry Market, By Application:

• Diagnostics
• Cancer
• Infectious Diseases
• Cardiovascular Diseases
• Autoimmune Diseases
• Diabetes Mellitus
• Nephrological Diseases
• Research

Immunohistochemistry Market, By End User:

• Hospitals & Diagnostic Laboratories
• Research Institutes
• Others

Immunohistochemistry Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Immunohistochemistry Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.